TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants
Brief Summary: The safety and efficacy of Intermittent Preventive Treatment for malaria and anaemia control in Infants (IPTi) have already been documented in Southern Tanzania, affording an opportunity to gain operational experience in developing a strategy for the longer-term implementation of IPTi. Working in conjunction with national and district-based health authorities, a strategy will be developed to make IPTi available through routine health services and an effectiveness evaluation conducted. This will be based on the comparison of process and outcome indicators in areas with and without IPTi. Information on safety will be consolidated and the effect of IPTi on the rate of development of drug resistance explored. The acceptability and costs of implementing IPTi will be monitored and combined with assessments of effectiveness (in terms of morbidity and mortality) to assess the cost-effectiveness of IPTi.


Options:
A: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
C: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine used for IPTi, Drug: IPTi | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine used for IPTi; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: IPTi; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
Brief Summary: This controlled study is designed to evaluate the efficacy of TS-1 on survival compared with surgery alone. Patients will be randomly assigned to receive either surgery alone or surgery followed by treatment with TS-1 within 45 days after curative resection (curability A or B). To assess the efficacy, data on recurrence and survival will be collected from the time of enrollment until 5 years after surgery. To evaluate safety, data on adverse events will be collected from the time of enrollment until 1 year after surgery.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 (S-1) | Arm Label: 2; Type: OTHER; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: TS-1 (S-1); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): 2
B: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
C: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group
D: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety (Including Bone Density Assessment) of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata
Brief Summary: The objective of this study is to determine the safety and effectiveness of asoprisnil in symptomatic women with abnormal uterine bleeding associated with uterine fibroids.


Options:
A: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)
Brief Summary: An evidence-based quality improvement intervention will overcome multiple barriers to best practice and improve rates of diagnosis and effective treatment for osteoporosis in high-risk patients. The intervention will be directed at patients (education and counseling) and their primary care physicians (reminders and opinion leader generated and endorsed single page guidelines)


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Use of Xrays for diagnosis | Intervention Type: BEHAVIORAL; Name: Use of Xrays for diagnosis; Assigned to Arm(s): Arm 1
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
D: Arm Label: physician chart reminder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder | Arm Label: chart reminder, educational mat'ls, FIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder, Behavioral: chart reminder, educational mat'ls, FIT | Arm Label: CR, ed mat'ls, FIT, phone call; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder, Behavioral: CR,ed mat'ls, FIT, phone call | Intervention Type: BEHAVIORAL; Name: Physician chart reminder; Assigned to Arm(s): CR, ed mat'ls, FIT, phone call, chart reminder, educational mat'ls, FIT, physician chart reminder | Intervention Type: BEHAVIORAL; Name: chart reminder, educational mat'ls, FIT; Assigned to Arm(s): chart reminder, educational mat'ls, FIT | Intervention Type: BEHAVIORAL; Name: CR,ed mat'ls, FIT, phone call; Assigned to Arm(s): CR, ed mat'ls, FIT, phone call

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)
Brief Summary: An evidence-based quality improvement intervention will overcome multiple barriers to best practice and improve rates of diagnosis and effective treatment for osteoporosis in high-risk patients. The intervention will be directed at patients (education and counseling) and their primary care physicians (reminders and opinion leader generated and endorsed single page guidelines)


Options:
A: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
C: Intervention Type: BEHAVIORAL; Name: Allied health professional-run osteoporosis service ("case-management"); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)
Brief Summary: An evidence-based quality improvement intervention will overcome multiple barriers to best practice and improve rates of diagnosis and effective treatment for osteoporosis in high-risk patients. The intervention will be directed at patients (education and counseling) and their primary care physicians (reminders and opinion leader generated and endorsed single page guidelines)


Options:
A: Arm Label: MJAP Clinics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: START | Arm Label: MJAP Clinics Pre-Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: START; Assigned to Arm(s): MJAP Clinics Intervention
B: Intervention Type: BEHAVIORAL; Name: Evidence summaries endorsed by local opinion leaders; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Quality Initiative in Rectal Cancer (QIRC) strategy; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)
Brief Summary: An evidence-based quality improvement intervention will overcome multiple barriers to best practice and improve rates of diagnosis and effective treatment for osteoporosis in high-risk patients. The intervention will be directed at patients (education and counseling) and their primary care physicians (reminders and opinion leader generated and endorsed single page guidelines)


Options:
A: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
B: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case-based customized learning | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case based customized learning + leader feedback | Intervention Type: BEHAVIORAL; Name: Simulated case-based customized learning; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Simulated case based customized learning + leader feedback; Assigned to Arm(s): Group C
C: Intervention Type: BEHAVIORAL; Name: Opinion leader generated and endorsed evidence summaries; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)
Brief Summary: An evidence-based quality improvement intervention will overcome multiple barriers to best practice and improve rates of diagnosis and effective treatment for osteoporosis in high-risk patients. The intervention will be directed at patients (education and counseling) and their primary care physicians (reminders and opinion leader generated and endorsed single page guidelines)


Options:
A: Intervention Type: BEHAVIORAL; Name: Falls, Fractures & Osteoporosis Risk Assessment & Management; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
Brief Summary: Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.


Options:
A: Arm Label: CDP870 100mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 100mg | Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 200mg | Arm Label: CDP870 400mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 400mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870 400mg; Assigned to Arm(s): CDP870 400mg | Intervention Type: DRUG; Name: CDP870 200mg; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: CDP870 100mg; Assigned to Arm(s): CDP870 100mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
B: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
C: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Certolizumab pegol (CDP870); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
Brief Summary: Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.


Options:
A: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
B: Arm Label: Open-label Abatacept (ABA)-Previous User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Arm Label: Open-label ABA-Current User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Arm Label: Long-term ABA; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD); Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Anti-Tumor Necrosing Factor (TNF) Therapy; Assigned to Arm(s): Open-label ABA-Current User
C: Intervention Type: DRUG; Name: Certolizumab pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870
Brief Summary: A 26 week maintenance study of CDP870 in Crohn's disease


Options:
A: Arm Label: Active 1; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol, Other: Placebo | Arm Label: Active 2; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Active 1 | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Active 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Active 1
B: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CDP870) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): Certolizumab Pegol
C: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg

Answer: C